Transplanting an animal organ into a human is now a closer reality following the successful xenotransplantation of a genetically modified pig liver into a patient diagnosed with brain death in China. The operation was intended to evaluate organ function over a 10-day period. This is a complex experimental trial that did not involve removing the patient's liver and still requires further study. However, the positive preclinical results suggest this strategy could save the lives of those waiting for a human organ, at least in certain cases. Read More
Eight months after announcing the $18.5 million first tranche of its series A, Augustine Therapeutics has closed the oversubscribed round at $85 million and is now ready to begin clinical development of its novel histone deacetylase-6 (HDAC6) inhibitors. Read More
Hubble Therapeutics LLC has successfully closed a $7.3 million series A funding round to support progression of its lead candidate, HUB-101, into clinical trials. Read More
Palatin Technologies Inc. has obtained U.S. orphan drug designation for PL-7737 for leptin receptor (LEPR) deficiency, including obesity caused by this condition. Read More
Researchers from Guangdong Medical University published data from a study that aimed to identify novel biomarkers that would allow for comprehensive assessment of prognosis and immunotherapy response in patients with testicular germ cell tumors (TGCT). Read More
In a study published in Nature Neuroscience, researchers from Tiziana Life Sciences Ltd. and collaborators investigated the potential of nasal delivery of the CD3 foralumab to reduce neuroinflammation and enhance microglial phagocytosis in a traumatic brain injury (TBI) model. Read More
Work at Satellos Bioscience Inc. has led to the identification of new AP2-associated protein kinase 1 (AAK1) inhibitors reported to be useful for the treatment of muscular dystrophy. Read More
Writing in Cell Reports, researchers from the National Institute of Allergy and Infectious Diseases (NIAID) and collaborators have presented a multifaceted analysis and structure-function study of a panel of human monoclonal antibodies (hmAbs) targeting AMA1 elicited by natural Plasmodium falciparum infection in a malaria-endemic region in Mali. Read More
Researchers from Edgewise Therapeutics Inc. have previously developed and characterized a novel bmx mouse model of Becker muscular dystrophy (BMD), which harbors a deletion of murine Dystrophin exons 45-47 on a C57/BL6J background. Read More
Theranocure Co. Ltd. has prepared and tested new vanillic acid derivatives targeting the dopamine D1 receptor (D1R) reported to be useful for the treatment of neuroinflammation and Alzheimer’s disease. Read More
Memorial Hospital for Cancer and Allied Diseases and Memorial Sloan Kettering Cancer Center have jointly developed new nonsteroid selective androgen receptor modulators (SARMs) and radiolabeled compounds reported to be useful for the diagnosis and treatment of cancer. Read More
Researchers from Shanghai Institute of Materia Medica of the Chinese Academy of Sciences and China Pharmaceutical University presented the discovery of novel orally bioavailable inhibitors of transient receptor potential canonical channels 4 and 5 (TRPC4/5), being developed for the treatment of depression and anxiety. Read More
Hepatocellular carcinoma (HCC) represents about 90% of all cases of liver cancer and has a poor prognosis, with a 5-year survival rate of about 18%. Previous findings had shown that RNA 5-methylcytosine (m5C) plays an important role in HCC progression, where the impairment of ferroptosis plays a crucial role in HCC progression. Read More
A Bristol Myers Squibb Co. patent detailed new substituted phenyl oxooxazolyl piperidine dione molecular glue degraders acting as DNA-binding protein Ikaros (IKZF1), zinc finger protein Helios (IKZF2), Aiolos (IKZF3) and Eos (IKZF4) degradation inducers potentially useful for the treatment of cancer. Read More
Pleco Therapeutics BV has held a successful pre-IND meeting with the FDA to discuss the continued development of PTX-252, an intravenous formulation designed to treat patients with acute myeloid leukemia (AML). Read More
Agios Pharmaceuticals Inc. has patented new 4-pyrazolo[1,5-a]pyridin-2-yl-4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine derivatives acting as phenylalanine hydroxylase (PAH) R408W mutant stabilizers reported to be useful for the treatment of phenylketonuria. Read More
Additional early-stage research and drug discovery news in brief, from: Mitsubishi Tanabe Pharma, NMD Pharma, Soligenix, Tenaya Therapeutics, Tharimmune, Theralase Technologies, Traws Pharma. Read More
